The frequency of CCNE1 amplification in EA primary tumors was 5.3% versus 9.1% in metastatic samples (P = 0.0061, Fisher exact test), with an amplification rate of 7.6% in lung metastases, 8.8% in liver metastases, 9.5% in lymph node metastases, 10% in brain metastases, and 16.1% in connective/soft tissue metastases. This evidence concerns the gene CCNE1 and metastatic malignant neoplasm in the lymph nodes.